Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular ...

Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in ...

Major scientific discoveries can arise from simple decisions: say, by simply looking where virtually no one else has. Such was the case for Ines Ibañez-Tallon, a research associate professor in the ...

Canadian drug developer Theratechnologies Inc. is in play. The Montreal-based company, known for its treatments for HIV patients, said late Friday that it’s in negotiations on a deal to sell ...

Current GLP-1 RA drugs, such as semaglutide and the dual glucagon-insulinotropic peptide (GIP)/GLP-1 tirzepatide, are approved for treating type 2 diabetes (T2D) (Ozempic and Mounjaro ...

National Institute for Health and Care Excellence (NICE), the spending watchdog for the NHS, has recommended the drug to be used in combination with AstraZeneca’s already-marketed breast cancer drug ...

Claims that a Texas-based drug compounder violated state unfair-competition laws when it decided to manufacture and sell copycat versions of a rheumatoid arthritis drug are not preempted by federal ...

At first, the biosimilars approved in the U.S. mainly were medications administered in clinical settings, such as biosimilars for Janssen’s rheumatoid arthritis medication Remicade and Amgen’s ...

were statistically significantly associated with decreased risk of Alzheimer disease and related dementias compared with other glucose-lowering drugs, and no difference was observed between both drugs ...

In particular, the finding that GLP-1 RA drugs may perform better than SGLT-2i drugs “suggests that the dementia protection effects are not due to glucose control mechanisms” and that ...